Trial Profile
A phase 1/2 multicenter, open label, dose ranging study of DN-101 [calcitriol] and Taxotere [docetaxel] in patients with advanced (stage IIIB or IV) non-small cell lung cancer (NSCLC) who have failed previous therapy with platinum-based chemotherapy
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 23 Jul 2007
Price :
$35
*
At a glance
- Drugs Calcitriol (Primary) ; Docetaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 09 Sep 2005 New trial record.